Plato Investment Management Ltd reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 83.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,503 shares of the biopharmaceutical company's stock after selling 31,807 shares during the quarter. Plato Investment Management Ltd's holdings in Royalty Pharma were worth $166,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RPRX. SBI Securities Co. Ltd. purchased a new position in shares of Royalty Pharma during the 4th quarter worth approximately $1,366,000. Riverview Trust Co grew its holdings in Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares during the last quarter. Metis Global Partners LLC increased its position in Royalty Pharma by 65.0% during the fourth quarter. Metis Global Partners LLC now owns 35,861 shares of the biopharmaceutical company's stock worth $915,000 after buying an additional 14,124 shares in the last quarter. US Bancorp DE raised its holdings in shares of Royalty Pharma by 151.3% in the fourth quarter. US Bancorp DE now owns 9,565 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 5,759 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Royalty Pharma in the fourth quarter valued at $786,000. Institutional investors and hedge funds own 54.35% of the company's stock.
Royalty Pharma Trading Down 0.8 %
RPRX traded down $0.27 during trading on Friday, hitting $33.01. The company's stock had a trading volume of 5,407,966 shares, compared to its average volume of 4,474,442. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The firm's 50 day moving average price is $30.87 and its 200-day moving average price is $28.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market cap of $19.03 billion, a PE ratio of 22.77, a PEG ratio of 2.31 and a beta of 0.47.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.
Royalty Pharma Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be given a $0.22 dividend. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.67%. Royalty Pharma's dividend payout ratio (DPR) is currently 60.69%.
Analyst Upgrades and Downgrades
Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Royalty Pharma has a consensus rating of "Buy" and an average target price of $41.60.
Get Our Latest Stock Report on Royalty Pharma
Royalty Pharma Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
